For the year ending 2025-12-31, GMED had -$258,282K decrease in cash & cash equivalents over the period. $588,768K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 537,868 |
| Bargain purchase gain | 117,704 |
| Acquired in-process research and development | 0 |
| Depreciation and amortization | 276,842 |
| Provision for excess and obsolete inventory | 22,119 |
| Amortization of acquisition accounting fair value step-up | 26,112 |
| Stock-based compensation expense | 49,779 |
| Allowance for expected credit losses | 10,223 |
| Change in fair value of business acquisition liabilities | 13,462 |
| Change in deferred income taxes | 18,625 |
| (gain)/loss on disposal of assets, net | -12,525 |
| Payment of business acquisition-related liabilities | 17,018 |
| Net (gain)/loss from foreign currency adjustment | -12,591 |
| Accounts receivable | 52,182 |
| Inventories | 17,598 |
| Prepaid expenses and other assets | -11,132 |
| Accounts payable | 8,487 |
| Accrued expenses and other liabilities | 34,217 |
| Income taxes payable/receivable | -50,851 |
| Net cash provided by/(used in) operating activities | 753,447 |
| Purchases of marketable securities | 107,531 |
| Maturities of marketable securities | 63,880 |
| Sales of marketable securities | 115,608 |
| Purchases of property and equipment | 164,679 |
| Acquisition of businesses, net of cash acquired and purchases of intangible and other assets | 252,546 |
| Acquisition of intangible assets | 9,746 |
| Net cash provided by/(used in) investing activities | -355,014 |
| Payment of business acquisition-related liabilities | 15,572 |
| Net proceeds from exercise of stock options | 89,757 |
| Payments related to tax withholdings for share-based compensation | 2,909 |
| Repurchase of common stock | 300,451 |
| Repayment of senior convertible notes | 449,985 |
| Net cash provided by/(used in) financing activities | -679,160 |
| Effect of foreign exchange rates on cash | 22,445 |
| Net increase/(decrease) in cash and cash equivalents | -258,282 |
| Cash and cash equivalents at beginning of period | 784,438 |
| Cash and cash equivalents at end of period | 526,156 |
GLOBUS MEDICAL INC (GMED)
GLOBUS MEDICAL INC (GMED)